Research status and progression in anti-angiogenesis therapy for pancreatic cancer

Mengting TONG,Hongming PAN,Da LI

DOI: https://doi.org/10.3969/j.issn.1009-0460.2018.03.016

2018-01-01

Chinese Clinical Oncology

Abstract:With the deeper research and development of anti-angiogenesis drugs, anti-angiogenesis therapy has become a hot spot in the field of pancreatic cancer. The exploration of anti-angiogenesis therapy for pancreatic cancer is mainly concentrated on drugs that target the vascular endothelial growth factor (VEGF), human epidermal growth factor receptor (HER) family, the phosphatidylinositol-3-kinase/protein kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway, as well as some traditional drugs, including matrix metalloproteinase inhibitors and cyclooxygenase-2 inhibitors. In the treatment of pancreatic cancer, the agents which target VEGF signaling pathway include the anti-VEGF monoclonal antibody, the anti-VEGFR drugs (sorafenib, sunitinib, axitinib and vandetanib), and the soluble recombinant fusion protein (aflibercept). The representative targeted drugs relevant to HER family are cetuximab and erlotinib. Everolimus aimed at PI3K/Akt/mTOR signaling pathway also have shown great prospect in the phase Ⅱ clinical trials. Currently, just only erlotinib has been completed the phase 3 clinical trials and succeeded. In future, researches should focus on multi-target agents or applications in combination two or three anti-angiogenesis drugs, traditional cytotoxic drugs and even immunomodulatory drugs in the treatment of pancreatic cancer. This review is performed by collecting the recent researches and clinical trials to summarize the current state and progress of research on anti-angiogenesis therapy in pancreatic cancer.